Captisol-Enabled Melphalan Meets Primary Endpoint in Melanoma Trial

The study's main objective was to determine the treatment's overall safety and toxicity profile in patients with multiple myeloma receiving 200 mg/m2 of CE melphalan as myeloablative therapy prior to autologous stem cell transplantation.

http://ift.tt/1jSMy9f